Hospital
NPI deactivated
Stoughton Hospital Association
Stoughton Hospital Association was paid $8.94M by Medicaid between Jan 2018 and Dec 2024, across 103 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 26% of everything it billed.
33Billing provider infoSTOUGHTON HOSPITAL ASSOCIATION
STOUGHTON, WI 53589
STOUGHTON, WI 53589
33aNPI1679558647assigned 12/13/2005
33bProvider typePsychiatric Hospital
28Total paid$8.94M
24GClaims154,487
24DCodes billed103
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital providers in Wisconsin
Rank by total paid#1 of 7
Median peer was paid$111K
This provider vs. median81×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 17,034 | $748K | |
| 2019 | 18,693 | $860K | |
| 2020 | 17,472 | $997K | |
| 2021 | 23,975 | $1.31M | |
| 2022 | 25,663 | $1.43M | |
| 2023 | 30,046 | $2.17M | |
| 2024incomplete | 21,604 | $1.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 26% | 18,174 | 14,664 | $2.30M |
| 96361 | Intravenous infusion, hydration; each additional hour | 12% | 2,950 | 2,118 | $1.11M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 12% | 7,345 | 6,154 | $1.10M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 8.4% | 5,144 | 3,683 | $753K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.6% | 3,188 | 2,375 | $415K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 1,636 | 1,197 | $314K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 3.5% | 1,662 | 1,455 | $309K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3.3% | 2,129 | 1,596 | $298K |
| 41899 | Unlisted procedure, dentoalveolar structures | 3.3% | 294 | 231 | $294K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 3.2% | 1,918 | 1,489 | $290K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 1,047 | 921 | $257K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 895 | 771 | $194K |
91 more codes
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 1.6% | 728 | $143K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 1.5% | 170 | $137K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.1% | 1,247 | $97K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 3,116 | $97K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,115 | $87K |
| 87631 | <1% | 877 | $82K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 741 | $74K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,459 | $73K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,545 | $53K |
| 80053 | Comprehensive metabolic panel | <1% | 6,251 | $50K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 420 | $39K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,785 | $39K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 101 | $27K |
| 87430 | <1% | 960 | $26K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 504 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,287 | $19K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 492 | $18K |
| 84484 | <1% | 2,924 | $18K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,672 | $16K |
| 81025 | <1% | 2,090 | $16K | |
| 83690 | <1% | 3,001 | $14K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,499 | $13K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 35 | $12K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,591 | $10K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 26 | $10K |
| 81001 | <1% | 3,644 | $9K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 46 | $9K |
| 95806 | <1% | 40 | $8K | |
| 83735 | <1% | 2,066 | $8K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,459 | $7K |
| 87400 | <1% | 763 | $7K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,250 | $7K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,652 | $7K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,130 | $5K |
| 81003 | <1% | 1,819 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 136 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 136 | $4K |
| 82077 | <1% | 503 | $3K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 17 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,797 | $3K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,823 | $3K |
| 83605 | <1% | 430 | $2K | |
| 87481 | <1% | 80 | $2K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 81 | $2K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 123 | $2K |
| 80306 | <1% | 147 | $2K | |
| 87077 | <1% | 359 | $2K | |
| 85610 | <1% | 633 | $2K | |
| 85379 | <1% | 300 | $2K | |
| 84703 | <1% | 294 | $2K | |
| 85027 | <1% | 328 | $1K | |
| 83880 | <1% | 106 | $1K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 6,177 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 70 | $913.96 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,334 | $868.57 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 110 | $853.36 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,005 | $804.57 |
| 87186 | <1% | 132 | $653.55 | |
| 73610 | <1% | 75 | $643.45 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 36 | $621.96 |
| 87040 | <1% | 108 | $603.66 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 53 | $353.43 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 24 | $351.42 |
| 84145 | <1% | 30 | $255.37 | |
| 87808 | <1% | 17 | $221.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,478 | $215.70 |
| 87420 | <1% | 16 | $212.22 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,936 | $208.44 |
| 80143 | <1% | 13 | $180.08 | |
| 87905 | <1% | 17 | $176.82 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 710 | $149.45 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,616 | $130.75 |
| 96376 | <1% | 646 | $119.99 | |
| 73030 | <1% | 14 | $110.01 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,595 | $99.58 |
| J2704 | Injection, propofol, 10 mg | <1% | 1,607 | $92.43 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 360 | $91.80 |
| 86140 | <1% | 21 | $80.25 | |
| 87220 | <1% | 19 | $66.15 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,848 | $58.46 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,617 | $40.48 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 630 | $32.57 |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 282 | $30.60 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 338 | $21.12 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 35 | $9.13 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 61 | $2.47 |
| 73110 | 0% | 16 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 47 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 180 | $0.00 |
| G0378 | Hospital observation service, per hour | 0% | 18 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDEGROOT, DANIEL (PRESIDENT)